Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker. Weber – who was briefly chief operating officer of Takeda ...

currently president of Takeda’s U.S. Business Unit, as the successor to Christophe Weber, Takeda’s president, chief executive officer (CEO) and representative director, when Mr. Weber retires ...

Takeda has been restructured under new CEO Christophe Weber, who took over in 2014 and has focused the company on cancer and specialist gastrointestinal drugs, and early stage central nervous ...

Another example of the trend in a country where countless numbers of Japanese study English even after their school days are long over concerns Takeda ... which appointed Christophe Weber from ...

Takeda has bolstered its near-term pipeline in rare haematological disorders by licensing rights to a polycythaemia vera (PV) treatment being developed by Protagonist Therapeutics. The Japanese ...

Three years after it was formed as a spinout of Japanese drugmaker Takeda, Phathom Pharmaceuticals has racked up its first FDA approvals, and claimed a sizeable $260 million in new financing to ...

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers ...

Anglo-US biotech NodThera has named former Jazz Pharma executive Dan Swisher as its new chief executive, replacing Alan Watt, who will take on the dual roles of president and chief scientific ...

BioMarin Pharmaceutical has made a couple of appointments aimed at boosting its pipeline, both internally and externally, with C-suite appointments in charge of R&D and business development.